ZBIO - Biotech: Take It On The Run
A recent study from Cowen Research says that biotech investors shouldn’t count on sell-side analysts’ ratings of stocks in the sector. In fact, biotech investors should do the exact opposite of their recommendations, and buy when analysts say sell, and vice versa. According to the report, the worse a stock’s rating, the better its performance the following year. If sell side analysts can’t accurately predict biotech stocks’ performance, what’s an investor to do?
Read Seeking Alpha, of course, and follow a biotech investing expert like Jonathan Faison, who’s created an entire system of discovering